Pfizer, Merck And Sanofi Show Interest In Priority Review Voucher Program
Executive Summary
The process for "cashing in" a priority review voucher needs further clarification, three big pharma companies agree
You may also be interested in...
Priority Review Voucher's Uncertain Value May Hinder Development
FDA’s innovative priority review voucher, intended to incentivize the development of new drugs for neglected diseases, may actually have created a hurdle in some cases.
Priority Review Voucher's Uncertain Value May Hinder Development
FDA’s innovative priority review voucher, intended to incentivize the development of new drugs for neglected diseases, may actually have created a hurdle in some cases.
Rare Disease Drugs Need Faster Development Track, Sen. Brownback Tells FDA
Sen. Sam Brownback, R-Kansas, told FDA it should establish a second track for the development and approval of drugs for rare and neglected diseases